• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Biolase Inc.

    1/13/23 4:15:39 PM ET
    $BIOL
    Medical/Dental Instruments
    Health Care
    Get the next $BIOL alert in real time by email
    SC 13G 1 sched13g.htm



     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No.   )*
     

     
    BIOLASE, INC.
     
     
    (Name of Issuer)
     

     
    Common Stock, par value $0.001 per share
     
     
    (Title of Class of Securities)
     

     
    090911405
     
     
    (CUSIP Number)
     

     
    January 10, 2023
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Fund II LP
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
    2,450,000
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    2,450,000
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,450,000(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%(2)
     
    12
    Type of Reporting Person (See Instructions)
    PN
     
    (1) The reporting person’s ownership consists of (i) 2,000,000 shares of common stock and (ii) 1,428,571 warrants to purchase shares of common stock (“Warrants”); however, due to the exercise limitations of the Warrants, the reporting person’s beneficial ownership of 978,571 Warrants is excluded.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.




    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Partners II LLC
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    2,450,000
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    2,450,000
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,450,000(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%(2)
     
    12
    Type of Reporting Person (See Instructions)
    OO
     
    (1) The reporting person’s ownership consists of (i) 2,000,000 shares of common stock and (ii) 1,428,571 Warrants; however, due to the exercise limitations of the Warrants, the reporting person’s beneficial ownership of 978,571 Warrants is excluded.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    2,450,000
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    2,450,000
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
    2,450,000(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%(2)
     
    12
    Type of Reporting Person (See Instructions)
     
    IN
     
    (1) The reporting person’s ownership consists of (i) 2,000,000 shares of common stock and (ii) 1,428,571 Warrants; however, due to the exercise limitations of the Warrants, the reporting person’s beneficial ownership of 978,571 Warrants is excluded.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.




    Item 1.
    (a)
    Name of Issuer
     
     
    BIOLASE, INC.
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    27042 Towne Centre Drive, Suite 270
    Lake Forest, California 92610
     

    Item 2.
    (a)
    Name of Person Filing
     
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •   Lind Global Fund II LP, a Delaware limited partnership;
    •   Lind Global Partners II LLC, a Delaware limited liability company; and
    •   Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
    (c)
    Citizenship
     
     
    See Row 4 of cover page for each Reporting Person.
     
    (d)
    Title of Class of Securities
     
    Common Stock, par value $0.001 per share
    (e)
    CUSIP Number
     
     
    090911405
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.
    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned
     
     
     See Row 9 of cover page for each Reporting Person.
     
    (b)
    Percent of Class
     
     
    See Row 11 of cover page for each Reporting Person.
     

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    See Row 5 of cover page for each Reporting Person.
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    See Row 6 of cover page for each Reporting Person.
     
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    See Row 7 of cover page for each Reporting Person.
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    See Row 8 of cover page for each Reporting Person.
     

    Item 5.  Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
    Item 6.  Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not Applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits     Exhibit

    99.1                  Joint Filing Agreement by and among the Reporting Persons.



    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    January 13, 2023

    LIND GLOBAL FUND II LP
       
    By:
     
    Lind Global Partners II LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS II LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    By:
     
    /s/ Jeff Easton


    Get the next $BIOL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Biolase Inc.

      SC 13G - BIOLASE, INC (0000811240) (Subject)

      2/23/24 4:05:29 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Biolase Inc.

      SC 13G - BIOLASE, INC (0000811240) (Subject)

      2/21/24 4:39:54 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Biolase Inc.

      SC 13G - BIOLASE, INC (0000811240) (Subject)

      2/14/24 4:06:57 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Yale Kenneth P.

      4 - BIOLASE, INC (0000811240) (Issuer)

      6/12/23 9:10:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Somerman Martha J. Dds, Phd

      4 - BIOLASE, INC (0000811240) (Issuer)

      6/12/23 9:08:49 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Roper Jess

      4 - BIOLASE, INC (0000811240) (Issuer)

      6/12/23 9:07:19 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Financials

    Live finance-specific insights

    See more
    • BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

      LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe

      8/8/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

      7/17/24 4:15:00 PM ET
      $BIOL
      $BTCY
      $DERM
      $ELUT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability

      Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and SuccessLAKE FOREST, CA / ACCESSWIRE / May 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024.First Quarter Financial HighlightsGenerated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialistsThird strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptionsGross margin was re

      5/13/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Colliers Securities resumed coverage on BIOLASE with a new price target

      Colliers Securities resumed coverage of BIOLASE with a rating of Buy and set a new price target of $1.15

      3/8/21 4:09:02 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • Maxim Group reiterated coverage on BIOLASE with a new price target

      Maxim Group reiterated coverage of BIOLASE with a rating of Buy and set a new price target of $2.00 from $1.00 previously

      1/26/21 4:24:15 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BIOLASE Voluntarily Initiates Chapter 11 Proceedings

      LAKE FOREST, CA / ACCESSWIRE / October 1, 2024 / BIOLASE, Inc. (NASDAQ:BIOL) (the "Company"), a global leader in dental lasers, today announced that the Company and its direct domestic subsidiaries have voluntarily initiated Chapter 11 proceedings (the "Bankruptcy Petitions") in the United States Bankruptcy Court for the District of Delaware (the "Court"). BIOLASE will seek Court approval to continue operating during the proceedings and remains focused on providing its customers with its award-winning dental lasers and customer service.The Company also announced today that it is pursuing a sale process under Section 363 of the Bankruptcy Code in conjunction with the filing. To this end, BIOL

      10/1/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

      LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe

      8/8/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

      7/17/24 4:15:00 PM ET
      $BIOL
      $BTCY
      $DERM
      $ELUT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)

    $BIOL
    SEC Filings

    See more
    • SEC Form 8-K filed by Biolase Inc.

      8-K - BIOLASE, INC (0000811240) (Filer)

      10/8/24 4:47:14 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • Biolase Inc. filed SEC Form 8-K: Bankruptcy or Receivership

      8-K - BIOLASE, INC (0000811240) (Filer)

      10/1/24 4:05:10 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Biolase Inc.

      8-K - BIOLASE, INC (0000811240) (Filer)

      9/6/24 4:05:08 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Leadership Updates

    Live Leadership Updates

    See more
    • Strateos Appoints Alexander K. Arrow as Chief Financial Officer and Expands Team

      Juliet M. Moritz appointed Vice President, Project Management Office Strateos, Inc., a pioneer in the development of remote access laboratories and lab automation software for life science research, today announced the appointment of Alexander K. Arrow, MD, CFA, as Chief Financial Officer. Dr. Arrow will join the Executive Leadership team and play a key role in leading the company's business and finance strategy focused on growth and new investments. The company has also named Juliet M. Moritz, MPH, Vice President, Project Management Office, reflecting the significant demand by large pharmaceutical companies and contract research organizations for deployment of Strateos Lodestar™ Software.

      2/8/23 8:00:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • BIOLASE NAMES DR. RUSSELL MORROW AS CHIEF DENTAL OFFICER

      Dr. Morrow brings extensive clinical, dental and DSO experience to help expand laser adoption globally LAKE FOREST, Calif., Oct. 13, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today announced the appointment of Russell Morrow, D.D.S. as Chief Dental Officer ("CDO"), effective November 1, 2022. Dr. Samuel Low, who has served as Chief Dental Officer since 2016, will be taking on a new role as Vice President, Clinical Strategic Alliances, where he will focus on building partnerships and growth with Dental Service Organizations (DSOs), universities and government institutions.

      10/13/22 6:30:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • BIOLASE Expands Core Capabilities As It Appoints Three New Board Members With Significant Dental Experience

      FOOTHILL RANCH, Calif., Aug. 16, 2021 /PRNewswire/ -- Demonstrating a deep commitment to expanding the core capabilities and diversity of its Board of Directors, BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced it has appointed three new board members to its Board of Directors (the "Board"), effective immediately. Drs. Kathleen T. O'Loughlin, Carol Gomez Summerhays, and Martha Somerman join a Board that has been instrumental in establishing and implementing the Company's business plan, which has demonstrated significant growth over the past several quarters.

      8/16/21 6:30:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care